Effectiveness of pneumococcal vaccination (20vPnC) to prevent all-cause pneumonia and lower respiratory tract infections among adults>=18 years old with an increased risk of pneumococcal disease at Kaiser Permanente Southern California
Pneumonia accounts for a substantial burden of morbidity and mortality among adults. Assessing the effectiveness of 20vPnC against all-cause pneumonia is critical to estimating the public health benefits of 20vPnC use among United States (US) adults in. These data may be used to guide implementation and use of pneumococcal conjugate vaccine (PnCs) among adults. While the 13vPnC estimates of vaccine effectiveness (VE) against all-cause outcomes were lower than those against vaccine-type (VT) outcomes, the actual impact of PnC against all-cause outcomes could be considerably greater than that estimated from VT outcomes.